The Senator was a leading voice supporting the nonprofit pharmaceutical model in 2021, and will be in 2022
San Francisco, CA – Today, Medicines360 CEO Tina Raine-Bennett, MD, MPH, released the following statement.
“The year 2021 will be remembered as a time the United States and the rest of the world faced incredible challenges. But it will also be remembered as a time of incredible innovation and bold leadership in the face of those challenges.
“At Medicines360, our core commitment has always been about removing barriers and increasing equitable access to essential medicines for women. As the pandemic, and the extreme economic challenges it has placed upon families continued last year, that core commitment felt more urgent than ever. That is why we have been so grateful for the bold leadership of U.S. Senator Jacky Rosen (D-NV).
“Faced with the urgent need to lower the cost of medicines for patients and to equitably increase access to care, Sen. Rosen looked beyond the options federal lawmakers typically discuss and sought out new solutions. As a critical part of her work, she introduced and championed the Expanding Access to Affordable Prescription Drugs and Medical Devices Act (S. 2257), a bill designed to support nonprofit pharmaceutical organizations like Medicines360 to sustainably increase access to affordable medicines for Americans.
“We thank Sen. Rosen for her visionary leadership and commitment to improving affordability and access to care for all people. By declaring that the nonprofit pharmaceutical model should be part of the solution, she forged a critical path towards a more equitable health care system. We look forward to continuing on that path beside her — throughout 2022 and beyond.”
The Expanding Access to Affordable Prescription Drugs and Medical Devices Act would improve the ability of nonprofit pharmaceutical organizations to sustainably provide affordable medicines to U.S. patients in a number of ways. It would enhance their ability to qualify for federal tax-exempt status, provide financial support to nonprofits working to develop and manufacture needed drugs, waive burdensome Food & Drug Administration (FDA) user fees, and provide new opportunities for priority FDA review for certain drugs developed by nonprofits.
Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit www.medicines360.org